Novoseven - Supply of the active substance EPTACOG ALFA (recombinant DNA Factor VII) vials

This tender involves the supply of EPTACOG ALFA, a recombinant DNA Factor VII, in vials. The contracting authority is the Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone di Palermo, located in Palermo, Italy. The tender is categorized under various medicinal products with a specific focus on the provision of this active pharmaceutical ingredient. The contract nature is classified as supplies, and the procurement procedure is a negotiated procedure without prior publication of a tender. The estimated value of the contract is EUR 475,180.50, with the awarded contract going to Novo Nordisk SPA for a total value of EUR 475,179.50. Interested parties can access the tender documents through the provided link to the official website of the contracting authority. This procurement is essential for ensuring the availability of EPTACOG ALFA, which plays a critical role in medical treatments involving blood coagulation disorders. The tender highlights the importance of timely and efficient supply chain management in the healthcare sector.

This is a supplies contract in the general supplies sector, with a focus on General Supplies. Located in Italy, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 475,181.

Published through ANAC (Italy), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the general supplies sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.